BridgeMD
Clinical and endocrinological effects of letrozole during the luteal phase after controlled ovarian stimulation in oocyte donors: a low interventional, randomized, controlled trial
EU CTIS ID: 2022-502586-21-00
What this study is testing
to determine whether the use of letrozole during the luteal phase in oocyte donors diminishes the ovarian volume
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Women who have been accepted into IVI's oocyte donation programme. - Age between 18 and 34 years, inclusive. - Hyperresponsiveness to stimulation, defined as the presence of ≥18 follicles of size ≥11 mm on the day of the last ultrasound control visit prior to ovarian puncture. - Dated and signed informed consent.
You likely can't join if
- - Known allergy to letrozole. - Known lactose intolerance. - Participation in another clinical study, prior to inclusion in the present study, which could affect the objectives of the study in the opinion of the investigator.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.